| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.05 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.055 | 0.06 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.064 | 0.06 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.057 | 0.06 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.065 | 0.07 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | -0.091 | 0.07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.059 | 0.07 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.07 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.07 |